Together, cancer meets its match
Omico is a government-backed national network of leading researchers, clinicians and industry partners that’s using precision medicine to unlock new potential in Australian research and turn the tide on cancer. With fast-tracked molecular screening, biomarker-led trial set up and patient enrolment from the entire nation we’re accelerating access to next-generation treatments and preventive strategies, improving outcomes for all Australians affected by cancer.
What we do
- Promoting precision medicine, a game changer in the fight against cancer
- Uniting Australia’s world-class cancer institutes, researchers, industry partners and government like never before
- Providing free molecular screening to 25,000 Australians with cancer to match them to innovative new treatments in clinical trials
How Omico can help you
Meet your clinical trial objectives sooner and for a lower cost.
Meet intellectually-stimulating research that changes cancer care and transforms lives.
Meet accelerated access to innovative new therapies for your patients.
Who we work with
Pioneering national genomics initiative gives 23,000 Australians their best fighting chance against the toughest cancers
As of March 2023, we have screened more than 7,000 patients through our Molecular Screening & Therapeutics (MoST) study.
Ground-breaking Australian research answers long-standing genetic mystery of why people develop rare hidden cancer
Research led by Omico, the Garvan Institute of Medical Research and UNSW Sydney has generated the first comprehensive genetic map of sarcomas, identifying several new important genes that when inherited can cause this deadly cancer. The research has wide implications for people living with sarcoma and their families – allowing detection of the cancer earlier and potentially improving survival for patients.